Novartis AG ADR
$ 152.08
-0.85%
15 Apr - close price
- Market Cap 298,164,716,000 USD
- Current Price $ 152.08
- High / Low $ 154.10 / 150.86
- Stock P/E 21.60
- Book Value 24.18
- EPS 7.15
- Next Earning Report 2026-05-05
- Dividend Per Share $4.67
- Dividend Yield 3.07 %
- Next Dividend Date -
- ROA 0.11 %
- ROE 0.31 %
- 52 Week High 165.43
- 52 Week Low 101.83
About
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Analyst Target Price
$153.26
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-04 | 2025-10-28 | 2025-07-17 | 2025-04-29 | 2025-01-30 | 2024-10-28 | 2024-07-17 | 2024-04-22 | 2024-01-30 | 2023-10-24 | 2023-07-17 | 2023-04-25 |
| Reported EPS | 2.03 | 2.25 | 2.42 | 2.28 | 1.98 | 2.06 | 1.97 | 1.8 | 1.53 | 1.74 | 1.83 | 1.71 |
| Estimated EPS | 2 | 2.31 | 2.37 | 2.17 | 1.76 | 1.93 | 1.86 | 1.68 | 1.66 | 1.74 | 1.76 | 1.53 |
| Surprise | 0.03 | -0.06 | 0.05 | 0.11 | 0.22 | 0.13 | 0.11 | 0.12 | -0.13 | 0 | 0.07 | 0.18 |
| Surprise Percentage | 1.5% | -2.5974% | 2.1097% | 5.0691% | 12.5% | 6.7358% | 5.914% | 7.1429% | -7.8313% | 0% | 3.9773% | 11.7647% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 2.13 |
| Currency | USD |
Previous Dividend Records
| Mar 2026 | Apr 2025 | Apr 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-03-16 | 2025-04-25 | 2024-04-19 | 2023-03-20 | 2022-03-17 | 2021-03-15 | None | None | None | None |
| Amount | $4.772961 | $3.99399 | $3.7395445 | $3.4693612 | $3.3574492 | $3.3783783 | $3.0424917 | $2.865 | $2.977 | $2.717759 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NVS
2026-04-15 23:11:38
This article provides access to the book value per share for Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs (BCBA:NVSC) on the Buenos Aires Stock Exchange through TradingView. It directs users to the financial data section for the company.
2026-04-15 02:11:38
Novartis AG, a Swiss pharmaceutical company, is highlighted for its robust pipeline of innovative medicines, particularly in gene therapy, immunology, and oncology, positioning it for long-term growth in the healthcare sector. The company's strategic focus on research and development, combined with a diversified portfolio and global market presence, aims to drive significant returns for investors in the United States and other English-speaking markets. While analysts are cautiously optimistic about its strategic priorities and strong pipeline, potential risks include patent expirations and regulatory challenges.
2026-04-15 02:09:37
Novartis AG, a Swiss pharmaceutical giant, is positioned for growth due to its robust pipeline of breakthrough therapies in areas like gene therapy and immunology, making it a key play for long-term healthcare growth. The company's business model centers on R&D for transformative medicines, supported by a diversified portfolio including innovative drugs, a strong generics business via Sandoz, and a growing focus on radioligand therapies. Novartis' strategic focus on high-science assets, coupled with industry tailwinds like personalized medicine and regulatory support, aims to deliver sustained leadership and value for investors.
2026-04-14 22:09:37
Novartis AG is focusing on its Innovative Medicines division, with stronghold products in immunology, cardiology, and oncology, positioning it for steady growth despite ongoing patent expirations. The company's strategy includes investing heavily in R&D, divesting its generics business, and targeting high-margin drugs, which translates to predictable dividend growth and shareholder returns. Key risks involve patent cliffs for major drugs like Entresto and Cosentyx, increasing biosimilar competition, and potential impacts from U.S. drug pricing reforms, alongside pipeline setbacks.
2026-04-14 15:40:29
AI startup Anthropic has appointed Novartis CEO Vas Narasimhan to its board of directors, making him the first pharmaceutical executive to join the company's governing body. This move comes as Anthropic reportedly considers an initial public offering as early as this year. Narasimhan emphasized the importance of responsibly deploying technology in healthcare, particularly AI's role in advancing scientific challenges while ensuring ethical development and application.
2026-04-14 15:40:29
Novartis is building a strong portfolio of innovative drugs in cardiology, oncology, and immunology, positioning its stock as a defensive play with growth potential for investors. The company's strategy focuses on high-value drugs, supported by a robust R&D engine and a balance between innovative patented medicines and the stable revenue from its Sandoz generics arm. Analysts generally view Novartis positively, citing its free cash flow, dividend potential, and resilience to economic cycles, making it attractive for long-term, income-focused investors.
